Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2020 on file Net Income-$4.63M-$4.63MderivedN/M vs Q4 2020 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Operating Incomederived-$5,518,000N/M Operating Cash Flowderived-$5,143,000N/M Free Cash Flowderived-$5,143,000N/M ended Dec 31, 2021 · filed Mar 31, 2022 · 90 d after period end